Dr. Tariq Ghayur earned his Bachelor of Science degree in Physiology from University of Karachi, Pakistan and a Ph.D. in Immunology from McGill University, Montreal, Canada. He did his post-doctoral training at Dana Farber Cancer Institute, Boston and joined AbbVie (Abbott) in 1990.
Dr. Ghayur has worked on both small molecule and biologics programs. He has 30+ years of experience leading multi-disciplinary, cross-therapeutic area Biologics discovery programs and developing novel biologics platforms in different organizations – BASF Pharma 1990 – 2001; Abbott Laboratories 2002 – 2013 and AbbVie 2014 – 2021. Several Biologics programs resulted in clinical development candidates.
Dr. Ghayur led the team that pioneered the discovery and development of the Dual-variable Domain –Ig (DVD-Ig) bi-specific platform and other multi-specific platforms. Three DVD – Ig molecules entered clinical development for autoimmune and oncology indications. As a Distinguished Research Fellow and Head of Foundational Immunology Department (2016 – 2018) at AbbVie,
Dr. Ghayur led the team that defined the uptake, intracellular trafficking and degradation of anti-TNF antibodies resulting in the concept of anti-TNF ADC (Next-Gen anti-TNF), two anti-TNF ADC molecules are currently in clinical development. In addition, he initiated/supervised several programs (mAbs, bi-specifics & ADC) that are in various stages of AbbVie’s discovery pipeline.
Dr. Ghayur also proposed and implemented several corporate-wide (Abbott & AbbVie) collaborative initiatives to bring forward innovative concepts/programs. Dr. Ghayur has authored or co-authored more than 50 publications, is a co-inventor on more than 50 issued/pending patents and has delivered more than 100 invited talks at various venues.
Since retiring from AbbVie July 2021, Dr. Ghayur has taken up a position as Entrepreneur in Residence at FairJourney Biologics. His interest is in learning about / applying recent technical innovations to explore novel biology of targets to develop novel bio-therapeutics.